Loading company…
Stockholm-based developer of sevuparin, a polysaccharide therapy aimed at severe inflammatory conditions such as sepsis.
Modus Therapeutics AB develops sevuparin, a polysaccharide product that aims to modulate the immune response and reduce systemic inflammation in severe conditions. Founded in 2011 and based in Stockholm, Sweden, the company is at the Series A stage and has completed 4 deals. Its latest equity round was a SERIES A in February 2025 that raised SEK 140 mn, led by HealthCap. It also raised SEK 5 million in venture debt from returning investor Karolinska Development in February 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in